Global Lifestyle Drugs Market to Grow at a CAGR of 2.8% by 2017-2021, with Allergan, BMS, Eli Lilly & Pfizer Leading the Way - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Lifestyle Drugs Market 2017-2021" report to their offering.

The global lifestyle drugs market to grow at a CAGR of 2.87% during the period 2017-2021.

The report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

According to the report, one driver in the market is the lifestyle changes. Lifestyle changes such as physical inactivity, stress, consumption of fast foods, and limited intake of water can lead to the development of acne. Research studies report that people who are physically inactive are prone to develop insulin resistance compared with active individuals.

Insulin resistance leads to the production of higher levels of sebum in the skin, resulting in acne development. Research studies also put forth that excess insulin can increase the levels of androgens in the body. High levels of androgens also lead to an increased production of sebum in the skin, resulting in acne development.

Key vendors

  • Allergan
  • BMS
  • Eli Lilly
  • Pfizer

Other prominent vendors

  • AstraZeneca
  • Avanir Pharmaceuticals
  • Avolynt
  • Celtaxsys
  • Cerecor
  • Corcept Therapeutics
  • Cosmo Pharmaceuticals
  • CTC Bio
  • Others

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of lifestyle diseases

PART 06: Market landscape

PART 07: Pipeline landscape

PART 08: Market segmentation by therapy area

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Key vendor analysis

PART 17: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/vx57zf/global_lifestyle

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Anti-Obesity Drugs, Sexual and Reproductive Health Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Anti-Obesity Drugs, Sexual and Reproductive Health Drugs